RxDoctor Payments Data

Gayathri Morrareddy, MD

Internal Medicine · New Port Richey, FLNPI 1467652297

Payments from drug & device makers

$1,392in general payments, 2019–2025

Across 72 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$658
  • AstraZeneca$220
  • Boehringer Ingelheim$130
  • Bayer$122
  • Amarin Pharma, Inc.$85
  • Pfizer$44
  • plus $134 from 7 others

What the payments were for

  • Food & beverage$1,37799%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,392 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,374
Medicare patients
26
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$60,971
FarxigaDapagliflozin Propanediol62$56,912
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$44,723
JardianceEmpagliflozin31$38,570
XareltoRivaroxaban20$25,558
OzempicSemaglutide14$15,031
Dabigatran EtexilateDabigatran Etexilate Mesylate52$13,784
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$12,411
JanumetSitagliptin Phos/Metformin Hcl14$11,056
TradjentaLinagliptin13$10,274
SymbicortBudesonide/Formoterol Fumarate24$8,918
Celecoxib127$8,383
Aripiprazole22$8,301
LantusInsulin Glargine,hum.Rec.Anlog42$5,872
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen210$5,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$220$78,24197 claims
PfizerEliquis$44$60,97161 claims
Boehringer IngelheimJardiance, Tradjenta$130$48,84444 claims
GSKTrelegy Ellipta$658$44,72356 claims
Johnson & JohnsonXarelto$15$25,55820 claims
Novo NordiskOzempic$20$15,03114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in New Port Richey

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →